US2019169575A1PendingUtilityA1

Sc-beta cells and compositions and methods for generating the same

72
Assignee: HARVARD COLLEGEPriority: Jun 11, 2013Filed: Feb 11, 2019Published: Jun 6, 2019
Est. expiryJun 11, 2033(~6.9 yrs left)· nominal 20-yr term from priority
Inventors:Quinn P. PetersonFelicia J. PagliucaDouglas A. MeltonJeffrey R. MillmanMichael Saris SegelMads GurtlerAlireza RezaniaBenjamin Fryer
A61P 5/50A61P 5/48C12N 2501/117C12N 2501/41C12N 2506/22C12N 2501/16C12N 2501/40C12N 2501/385C12N 5/0696C12N 2501/11C12N 2501/375C12N 5/0676C12N 2506/02C12N 5/0678C12N 2501/999C12N 2501/15C12N 2506/45C12N 5/0606C12N 2501/727C12N 2501/998C12N 2501/395C12N 2506/03A61K 35/39A61P 3/10C12N 2500/38
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for differentiating PDX1-positive pancreatic progenitor cells into NKX6.1 positive pancreatic progenitor cells with a culture medium comprising a) KGF and b) SANT1, wherein the culture medium is substantially free of a Protein Kinase C (PKC) Activator. 
     
     
         2 . The method of  claim 1 , wherein the PKC Activator is Phorbol 12,13-dibutyrate (PdBu) or TPB. 
     
     
         3 . The method of  claim 1 , wherein the PKC Activator is PdBu. 
     
     
         4 . The method of  claim 1 , wherein the PCK Activator is TPB. 
     
     
         5 . The method of  claim 1 , further comprising retinoic acid (RA). 
     
     
         6 . A method for differentiating PDX1-positive pancreatic progenitor cells into NKX6.1 positive pancreatic progenitor cells with a culture medium comprising a) KGF and b) SANT1, wherein the culture medium is substantially free of a BMP signaling pathway inhibitor. 
     
     
         7 . The method of  claim 6 , wherein the BMP signaling pathway inhibitor is noggin, chordin, gremlin, and follistatin and LDN 193189 
     
     
         8 . The method of  claim 6 , wherein the BMP signaling pathway inhibitor is noggin. 
     
     
         9 . The method of  claim 6 , wherein the BMP signaling pathway inhibitor is chordin. 
     
     
         10 . The method of  claim 6 , wherein the BMP signaling pathway inhibitor is gremlin. 
     
     
         11 . The method of  claim 6 , wherein the BMP signaling pathway inhibitor is follistatin. 
     
     
         12 . The method of  claim 6 , wherein the BMP signaling pathway inhibitor is LDN 193189.

Join the waitlist — get patent alerts

Track US2019169575A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.